BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 24225201)

  • 1. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
    Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Robertson M; Ford I;
    Int J Cardiol; 2013 Dec; 170(2):182-8. PubMed ID: 24225201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
    Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
    Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
    Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
    Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart failure and COPD: time to SHIFT?
    Sanders-van Wijk S; van Empel V; Knackstedt C; Brunner-La Rocca HP
    Int J Cardiol; 2014 Mar; 172(2):293-4. PubMed ID: 24452222
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study.
    Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Ford I;
    Eur J Heart Fail; 2013 Nov; 15(11):1296-303. PubMed ID: 23803951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ivabradine in patients with stable angina receiving β-blockers according to baseline heart rate: an analysis of the ASSOCIATE study.
    Tardif JC; Ponikowski P; Kahan T;
    Int J Cardiol; 2013 Sep; 168(2):789-94. PubMed ID: 23138014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
    Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
    Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
    Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
    [No Abstract]   [Full Text] [Related]  

  • 12. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF).
    Mentz RJ; Wojdyla D; Fiuzat M; Chiswell K; Fonarow GC; O'Connor CM
    Am J Cardiol; 2013 Feb; 111(4):582-7. PubMed ID: 23200803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.
    Mentz RJ; Schmidt PH; Kwasny MJ; Ambrosy AP; O'Connor CM; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Gheorghiade M
    J Card Fail; 2012 Jul; 18(7):515-23. PubMed ID: 22748484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
    Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
    Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF.
    Mentz RJ; Fiuzat M; Wojdyla DM; Chiswell K; Gheorghiade M; Fonarow GC; O'Connor CM
    Eur J Heart Fail; 2012 Apr; 14(4):395-403. PubMed ID: 22302663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
    Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
    Ekman I; Chassany O; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L; Swedberg K
    Eur Heart J; 2011 Oct; 32(19):2395-404. PubMed ID: 21875859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease.
    Kubota Y; Asai K; Furuse E; Nakamura S; Murai K; Tsukada YT; Shimizu W
    Int J Chron Obstruct Pulmon Dis; 2015; 10():515-23. PubMed ID: 25784798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.